| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 49 | 2021 | 440 | 5.790 |
Why?
|
| RNA, Viral | 32 | 2018 | 149 | 3.910 |
Why?
|
| HIV Infections | 42 | 2021 | 980 | 3.060 |
Why?
|
| Specimen Handling | 7 | 2018 | 48 | 1.780 |
Why?
|
| Drug Resistance, Viral | 9 | 2020 | 37 | 1.700 |
Why?
|
| Viral Load | 19 | 2018 | 199 | 1.210 |
Why?
|
| Genome, Viral | 2 | 2020 | 12 | 1.140 |
Why?
|
| Laboratories | 11 | 2018 | 25 | 1.070 |
Why?
|
| Genotype | 10 | 2021 | 405 | 1.040 |
Why?
|
| Reagent Kits, Diagnostic | 10 | 2018 | 19 | 0.980 |
Why?
|
| DNA, Viral | 10 | 2011 | 96 | 0.820 |
Why?
|
| Sequence Analysis, DNA | 7 | 2020 | 73 | 0.800 |
Why?
|
| Quality Control | 5 | 2018 | 43 | 0.770 |
Why?
|
| RNA Stability | 2 | 2018 | 3 | 0.670 |
Why?
|
| Polymerase Chain Reaction | 10 | 2021 | 161 | 0.660 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2016 | 1 | 0.600 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2016 | 4 | 0.600 |
Why?
|
| Utilization Review | 1 | 2016 | 6 | 0.590 |
Why?
|
| Urinary Catheters | 1 | 2016 | 4 | 0.590 |
Why?
|
| Sensitivity and Specificity | 16 | 2018 | 553 | 0.580 |
Why?
|
| HIV Reverse Transcriptase | 5 | 2006 | 9 | 0.570 |
Why?
|
| Virology | 8 | 2012 | 14 | 0.530 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2012 | 47 | 0.530 |
Why?
|
| Plasma | 3 | 2015 | 34 | 0.500 |
Why?
|
| HIV Protease | 3 | 2006 | 9 | 0.480 |
Why?
|
| Humans | 61 | 2021 | 29361 | 0.450 |
Why?
|
| HIV | 7 | 2012 | 92 | 0.390 |
Why?
|
| Cytomegalovirus | 4 | 2007 | 76 | 0.380 |
Why?
|
| Genitalia, Female | 4 | 2005 | 28 | 0.370 |
Why?
|
| Anti-HIV Agents | 11 | 2006 | 171 | 0.370 |
Why?
|
| Diagnostic Errors | 3 | 2018 | 40 | 0.370 |
Why?
|
| HIV Core Protein p24 | 5 | 2007 | 29 | 0.360 |
Why?
|
| Desiccation | 1 | 2009 | 5 | 0.350 |
Why?
|
| Blood | 1 | 2009 | 25 | 0.350 |
Why?
|
| Base Sequence | 4 | 2020 | 135 | 0.310 |
Why?
|
| Blood Preservation | 2 | 2005 | 4 | 0.280 |
Why?
|
| Proviruses | 1 | 2005 | 9 | 0.270 |
Why?
|
| Cytomegalovirus Infections | 3 | 2007 | 79 | 0.260 |
Why?
|
| Consensus Sequence | 2 | 2020 | 4 | 0.260 |
Why?
|
| Phylogeny | 5 | 2021 | 63 | 0.260 |
Why?
|
| Cervix Uteri | 5 | 2009 | 38 | 0.250 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2003 | 6 | 0.250 |
Why?
|
| Quality Assurance, Health Care | 3 | 2013 | 49 | 0.250 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2003 | 19 | 0.240 |
Why?
|
| Reproducibility of Results | 12 | 2012 | 788 | 0.230 |
Why?
|
| Molecular Sequence Data | 6 | 2009 | 246 | 0.230 |
Why?
|
| Genotyping Techniques | 2 | 2012 | 10 | 0.220 |
Why?
|
| Mesons | 2 | 2012 | 5 | 0.210 |
Why?
|
| Mutation | 7 | 2006 | 383 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2009 | 145 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 37 | 0.190 |
Why?
|
| Female | 27 | 2021 | 16211 | 0.190 |
Why?
|
| Temperature | 4 | 2012 | 76 | 0.190 |
Why?
|
| Viral Proteins | 1 | 1999 | 24 | 0.180 |
Why?
|
| Virus Replication | 4 | 2009 | 92 | 0.180 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 101 | 0.170 |
Why?
|
| Biological Specimen Banks | 1 | 2018 | 5 | 0.160 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2009 | 111 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 7 | 2005 | 152 | 0.160 |
Why?
|
| Cryopreservation | 3 | 2008 | 24 | 0.160 |
Why?
|
| Young Adult | 3 | 2021 | 1935 | 0.150 |
Why?
|
| Disposable Equipment | 1 | 2016 | 2 | 0.150 |
Why?
|
| Germany | 1 | 2016 | 11 | 0.150 |
Why?
|
| Recombination, Genetic | 2 | 2009 | 13 | 0.150 |
Why?
|
| Needs Assessment | 1 | 2016 | 47 | 0.150 |
Why?
|
| Age Distribution | 1 | 2016 | 94 | 0.150 |
Why?
|
| Sex Distribution | 1 | 2016 | 87 | 0.140 |
Why?
|
| Patient Preference | 1 | 2016 | 33 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2016 | 641 | 0.140 |
Why?
|
| Adult | 11 | 2021 | 8604 | 0.140 |
Why?
|
| HIV Seropositivity | 5 | 2021 | 95 | 0.140 |
Why?
|
| Saliva | 2 | 2006 | 53 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 2 | 2015 | 52 | 0.140 |
Why?
|
| HIV Antibodies | 2 | 2006 | 42 | 0.140 |
Why?
|
| Vaginosis, Bacterial | 2 | 2005 | 30 | 0.130 |
Why?
|
| Adolescent | 3 | 2016 | 2280 | 0.130 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2013 | 1 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2021 | 3273 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 37 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 51 | 0.120 |
Why?
|
| Child | 2 | 2016 | 1345 | 0.110 |
Why?
|
| Prospective Studies | 8 | 2021 | 1812 | 0.110 |
Why?
|
| Spectrum Analysis | 1 | 2012 | 9 | 0.110 |
Why?
|
| Nuclear Physics | 1 | 2012 | 7 | 0.110 |
Why?
|
| Humidity | 2 | 2009 | 4 | 0.110 |
Why?
|
| Dried Blood Spot Testing | 1 | 2012 | 4 | 0.110 |
Why?
|
| Male | 12 | 2021 | 15637 | 0.110 |
Why?
|
| Middle Aged | 6 | 2021 | 9823 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2012 | 91 | 0.100 |
Why?
|
| Viremia | 3 | 2007 | 36 | 0.100 |
Why?
|
| Physics | 1 | 2011 | 4 | 0.100 |
Why?
|
| Drug Resistance, Microbial | 3 | 2002 | 96 | 0.100 |
Why?
|
| Hepatitis B virus | 1 | 2011 | 7 | 0.100 |
Why?
|
| Electrons | 1 | 2011 | 19 | 0.100 |
Why?
|
| Protons | 1 | 2012 | 81 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2011 | 19 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2003 | 30 | 0.100 |
Why?
|
| Aged | 4 | 2021 | 9447 | 0.090 |
Why?
|
| Democratic Republic of the Congo | 1 | 2009 | 2 | 0.090 |
Why?
|
| Sequence Homology | 1 | 2009 | 4 | 0.090 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 8 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2009 | 52 | 0.090 |
Why?
|
| Virus Shedding | 2 | 2007 | 13 | 0.090 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 2 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 63 | 0.090 |
Why?
|
| Blood Specimen Collection | 2 | 2006 | 11 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2007 | 140 | 0.080 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2006 | 28 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3476 | 0.080 |
Why?
|
| Vagina | 2 | 2004 | 46 | 0.080 |
Why?
|
| Reference Standards | 3 | 2003 | 33 | 0.080 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 14 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 4851 | 0.070 |
Why?
|
| Algorithms | 2 | 2002 | 400 | 0.070 |
Why?
|
| Lectins | 1 | 2006 | 4 | 0.070 |
Why?
|
| Polysaccharides | 1 | 2006 | 15 | 0.070 |
Why?
|
| Immune System | 1 | 2006 | 21 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2006 | 10 | 0.070 |
Why?
|
| Hepacivirus | 1 | 2006 | 73 | 0.070 |
Why?
|
| Substance-Related Disorders | 2 | 2003 | 104 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2013 | 90 | 0.070 |
Why?
|
| Monocytes | 1 | 2005 | 116 | 0.060 |
Why?
|
| Lactobacillus | 1 | 2004 | 19 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2002 | 97 | 0.060 |
Why?
|
| Receptors, HIV | 1 | 2003 | 6 | 0.060 |
Why?
|
| Cell Line | 2 | 2005 | 299 | 0.060 |
Why?
|
| Infant, Newborn | 4 | 2003 | 604 | 0.060 |
Why?
|
| International Cooperation | 1 | 2003 | 32 | 0.060 |
Why?
|
| Observer Variation | 1 | 2003 | 118 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 96 | 0.060 |
Why?
|
| Cytokines | 1 | 2005 | 348 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2000 | 193 | 0.060 |
Why?
|
| World Health Organization | 2 | 2012 | 18 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 5 | 0.050 |
Why?
|
| Philippines | 1 | 2021 | 5 | 0.050 |
Why?
|
| Gene Amplification | 2 | 2003 | 19 | 0.050 |
Why?
|
| Internal-External Control | 1 | 2001 | 8 | 0.050 |
Why?
|
| Vaginal Smears | 1 | 2000 | 17 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2000 | 11 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2000 | 28 | 0.050 |
Why?
|
| Receptors, CCR5 | 1 | 2000 | 28 | 0.050 |
Why?
|
| Semen | 1 | 2000 | 5 | 0.050 |
Why?
|
| Infant | 3 | 1998 | 531 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2000 | 965 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2013 | 30 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1999 | 16 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 1999 | 12 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 45 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 1999 | 21 | 0.050 |
Why?
|
| Biomarkers | 1 | 2003 | 692 | 0.050 |
Why?
|
| Macrophages | 1 | 2000 | 128 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2003 | 1184 | 0.040 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 1999 | 11 | 0.040 |
Why?
|
| Gene Expression | 1 | 1999 | 226 | 0.040 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 1997 | 1 | 0.040 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 1997 | 3 | 0.040 |
Why?
|
| Sulfates | 1 | 1997 | 16 | 0.040 |
Why?
|
| Carbohydrates | 1 | 1997 | 14 | 0.040 |
Why?
|
| Cohort Studies | 3 | 1999 | 1939 | 0.040 |
Why?
|
| Zidovudine | 2 | 1997 | 39 | 0.040 |
Why?
|
| Genes, Viral | 1 | 1996 | 8 | 0.040 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2006 | 19 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 1997 | 92 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 1996 | 44 | 0.040 |
Why?
|
| Forecasting | 1 | 1996 | 117 | 0.030 |
Why?
|
| Interleukin-6 | 2 | 2007 | 108 | 0.030 |
Why?
|
| Gardnerella vaginalis | 2 | 2005 | 6 | 0.030 |
Why?
|
| Mycoplasma hominis | 2 | 2005 | 6 | 0.030 |
Why?
|
| Colony Count, Microbial | 2 | 2005 | 23 | 0.030 |
Why?
|
| Glycosylation | 2 | 2006 | 24 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 1999 | 1829 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 2000 | 56 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2007 | 24 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 159 | 0.030 |
Why?
|
| Pregnancy | 3 | 2003 | 404 | 0.030 |
Why?
|
| Pathology | 1 | 2013 | 4 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 25 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2006 | 220 | 0.030 |
Why?
|
| Dideoxyadenosine | 1 | 1993 | 1 | 0.030 |
Why?
|
| United States | 3 | 2013 | 2332 | 0.030 |
Why?
|
| Particle Accelerators | 1 | 2012 | 6 | 0.030 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2012 | 1 | 0.030 |
Why?
|
| Mass Screening | 1 | 2013 | 177 | 0.030 |
Why?
|
| Culture Media | 2 | 2007 | 38 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 1996 | 1442 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 340 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2012 | 116 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 1999 | 324 | 0.020 |
Why?
|
| Time Factors | 3 | 2003 | 1618 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 3 | 1996 | 75 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 218 | 0.020 |
Why?
|
| Palatine Tonsil | 1 | 2009 | 7 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2009 | 40 | 0.020 |
Why?
|
| Rectum | 1 | 2009 | 61 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2002 | 241 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 213 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2002 | 676 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 23 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Phenotype | 2 | 2000 | 357 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 31 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 34 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2007 | 30 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2007 | 32 | 0.020 |
Why?
|
| Leukocytes | 1 | 2007 | 43 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2007 | 35 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2007 | 21 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2007 | 64 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2006 | 50 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2006 | 19 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 61 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 50 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 40 | 0.020 |
Why?
|
| Risk Factors | 2 | 2003 | 2446 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2006 | 106 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2006 | 97 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 76 | 0.020 |
Why?
|
| Templates, Genetic | 1 | 2005 | 2 | 0.020 |
Why?
|
| Codon | 1 | 2005 | 7 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2005 | 7 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2006 | 65 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2005 | 43 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2005 | 36 | 0.020 |
Why?
|
| Mycoplasma Infections | 1 | 2004 | 3 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2005 | 78 | 0.020 |
Why?
|
| Simplexvirus | 1 | 2004 | 9 | 0.020 |
Why?
|
| Vaginal Douching | 1 | 2004 | 9 | 0.020 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2004 | 6 | 0.020 |
Why?
|
| Candida | 1 | 2004 | 16 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2004 | 16 | 0.020 |
Why?
|
| Animals | 2 | 2006 | 4577 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 215 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2004 | 298 | 0.020 |
Why?
|
| Genes, env | 1 | 2003 | 5 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2003 | 66 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2003 | 95 | 0.010 |
Why?
|
| Skin | 1 | 2003 | 117 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2003 | 209 | 0.010 |
Why?
|
| Smoking | 1 | 2003 | 194 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2003 | 285 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2003 | 170 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 132 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 496 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 638 | 0.010 |
Why?
|
| Quail | 1 | 2000 | 1 | 0.010 |
Why?
|
| Giant Cells | 1 | 2000 | 3 | 0.010 |
Why?
|
| Receptors, CCR3 | 1 | 2000 | 2 | 0.010 |
Why?
|
| DNA Probes | 1 | 2000 | 7 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2000 | 11 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 521 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1999 | 96 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2000 | 321 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 1999 | 25 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 1998 | 37 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1999 | 324 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1999 | 340 | 0.010 |
Why?
|
| Survival Rate | 1 | 1999 | 349 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 130 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1998 | 170 | 0.010 |
Why?
|
| Herpes Simplex | 1 | 1997 | 1 | 0.010 |
Why?
|
| Bacterial Adhesion | 1 | 1997 | 5 | 0.010 |
Why?
|
| Neisseria gonorrhoeae | 1 | 1997 | 7 | 0.010 |
Why?
|
| Chlamydia trachomatis | 1 | 1997 | 18 | 0.010 |
Why?
|
| Gonorrhea | 1 | 1997 | 8 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1997 | 50 | 0.010 |
Why?
|
| Chlamydia Infections | 1 | 1997 | 8 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1997 | 13 | 0.010 |
Why?
|
| Freezing | 1 | 1997 | 14 | 0.010 |
Why?
|
| Time | 1 | 1997 | 18 | 0.010 |
Why?
|
| Didanosine | 1 | 1997 | 6 | 0.010 |
Why?
|
| Nevirapine | 1 | 1997 | 3 | 0.010 |
Why?
|
| Pyridines | 1 | 1997 | 42 | 0.010 |
Why?
|
| Blood Stains | 1 | 1996 | 1 | 0.010 |
Why?
|
| Prognosis | 1 | 1999 | 840 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1996 | 65 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1996 | 33 | 0.010 |
Why?
|
| Disease Progression | 1 | 1997 | 788 | 0.010 |
Why?
|
| Genes, gag | 1 | 1993 | 3 | 0.010 |
Why?
|
| Certification | 1 | 1993 | 49 | 0.010 |
Why?
|
| Professional Competence | 1 | 1992 | 39 | 0.010 |
Why?
|